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Abstract
Background: Extracting biological information from high-density Affymetrix arrays is a multi-step
process that begins with the accurate annotation of microarray probes. Shortfalls in the original
Affymetrix probe annotation have been described; however, few studies have provided rigorous
solutions for routine data analysis.
Results: Using AceView, a comprehensive human transcript database, we have reannotated the
probes by matching them to RNA transcripts instead of genes. Based on this transcript-level
annotation, a new probe set definition was created in which every probe in a probe set maps to a
common set of AceView gene transcripts. In addition, using artificial data sets we identified that a
minimal probe set size of 4 is necessary for reliable statistical summarization. We further
demonstrate that applying the new probe set definition can detect specific transcript variants
contributing to differential expression and it also improves cross-platform concordance.
Conclusion: We conclude that our transcript-level reannotation and redefinition of probe sets
complement the original Affymetrix design. Redefinitions introduce probe sets whose sizes may not
support reliable statistical summarization; therefore, we advocate using our transcript-level
mapping redefinition in a secondary analysis step rather than as a replacement. Knowing which
specific transcripts are differentially expressed is important to properly design probe/primer pairs
for validation purposes. For convenience, we have created custom chip-description-files (CDFs)
and annotation files for our new probe set definitions that are compatible with Bioconductor,
Affymetrix Expression Console or third party software.
Background
Affymetrix GeneChips™ [1,2] are widely used in biomedi-
cal research for genome-wide expression profiling. The
level of gene expression is typically summarized from a
probe set composed of several 25 mer probes designed to
span a target region based on a UniGene cluster. Summa-
rized expression measurements for a probe set are typi-
cally derived using a variety of algorithms, including
MAS5.0 [3], model-based-expression indices (MBEI) [4],
robust multi-chip-average (RMA) [5,6], and the position-
dependent nearest neighbor (PDNN) algorithm [7,8].
Significant effort has been placed on extracting accurate
and robust expression measurements summarized from
multiple probes using a variety of statistical algorithms [9-
11]. Recently, with the public release of microarray probe
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sequences, attention has been paid to the accuracy of indi-
vidual probe annotations and its impact on gene expres-
sion data [12-17]. Probes within a probe set can be both
ambiguous (non-specific, i.e. targeting multiple genes)
and heterogeneous (target different transcript variants
from one gene). For example, examination of the probe
sequences incorporated in the Affymetrix Human
Genome U95Av2 Array indicates that 10.5% of the probes
are nonspecific and 9.3% are mistargeted [16]. Moreover,
interpretation of probe signal is complicated by probes
cross-hybridizing to similar sequences and transcript vari-
ants from alternative splicing [15,16]. It should be noted
that grouping probes that map to different targets may cre-
ate divergent signals that will significantly influence
expression measurements from stochastic-model-based
summarization approaches (e.g. RMA). For example, stray
signal arising from probes with multiple targets within a
probe set have been shown to contribute to misleading
biological relationships [17]. A more nuanced approach
to estimating expression levels calls for consideration of
alternative splicing, as more than half of all genes are
alternatively spliced in the human genome [18]. While
use of the UniGene-based definition of Affymetrix probe
sets may be sufficient to provide overall differential gene
expression estimates, it is inadequate for distinguishing or
preserving signal data arising from different transcript var-
iants [15,19].
Several groups have explored the effects of using alterna-
tive microarray annotations. By matching probe
sequences to an up-to-date Reference Sequence (RefSeq)
database [20,21], Gautier et al [22] investigated an "alter-
native mapping" approach, wherein probes were grouped
together if they matched a common RefSeq transcript and
were excluded from a probe set if they matched 2 or more
RefSeq entries. While this approach increases the specifi-
city of each probe set, it might prove impractical in the
long term with the continued growth of the RefSeq data-
base, resulting in the erosion of probe sets over time.
Carter  et al [23] adopted a redefinition of Affymetrix
probe sets where probes were matched against cDNA
clones on spotted arrays. Their method showed improved
concordance of expression measurements, hinting that
concordant annotation would support concordance of
results. In contrast, when they used the AceView transcript
database to match Affymetrix probe sets containing
probes that could be sequence matched to the same tran-
script sequence as the cDNA clone (Shared Transcript
probes), they found relatively low cross-platform consist-
ency as compared to direct sequence overlap. They postu-
lated that the low correlation might be due to a number of
factors including the presence of splice variants, the
probes being subject to different cross-hybridization pat-
terns, or incorrect clone sequence predictions [23]. More
recently, Dai et al [13] provided a method for redefining
Affymetrix probe sets using several gene and transcript
databases. In their regrouping strategy, all probes that
match a single transcript or gene are simply grouped into
a probe set. These approaches however, did not account
for the heterogeneous manner in which individual probes
can target transcripts. Hence, the expression signal from a
given probe set is summarized across probes that individ-
ually map to varied and/or multiple sets of transcript var-
iants.
We propose here a new method for constructing probe
sets for Affymetrix GeneChips based on the AceView data-
base, a comprehensive listing of human transcripts
[24,25]. The key feature of our probe set definition
method is that all probes within a probe set match a com-
mon set of AceView transcripts. By doing so, transcript-
level annotations are more accurate because probes
regrouped within a given probe set homogeneously map
to a single transcript variant or a set of alternatively spliced
transcripts (see Figure 1). However, remapping probes in
this way can reduce the size of a probe set, raising con-
cerns of reliability [22,23]. Through a systematic evalua-
tion of standard datasets, we establish the minimum
probe set size required for deriving a robust expression
measurement. Finally, we demonstrate the usage of our
approach by reanalyzing actual gene expression data from
a biological experiment and measuring the concordance
between AceView transcript-matched data from two dif-
ferent platforms.
Results
Redefinition of Affymetrix probe sets
We regrouped probes into a probe set such that all probes
within a probe set match a common set of transcripts,
based on our current knowledge of the transcriptome
found in AceView. The first step was to map individual
probes to transcripts in the AceView database (see Meth-
ods). Our analysis found that the percentage of probe
sequences matching to transcripts in the AceView data-
base is very high; approximately 90% of the probes on the
GeneChips U95A, U133A, and about 80% on the Human
Genome U133A Plus 2.0 Array, were mapped to one or
more AceView transcripts (Table 1). In contrast, only
about 52% of the probes on U133 Plus 2.0 can be mapped
to the RefSeq collection.
Given a specific probe-to-transcript mapping, defining a
probe set is straightforward: probes that are mapped to the
same set of transcripts naturally belong to a common
probe set. There are two ways in which a new probe set can
be formed: it can be derived solely from a single Affyme-
trix probe set or it can be formed by merging probes from
2 or more Affymetrix probe sets. One example of the first
scenario is shown in Figure 1 (top panel). The Affymetrix
probe set 34666_at on the GeneChip U95Av2 contains 16BMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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An example of grouping Affymetrix probes into new probe sets Figure 1
An example of grouping Affymetrix probes into new probe sets. The top panel shows an AceView diagram demon-
strating an example of the regrouping strategy. The Affymetrix probe set "34666_at" (on GeneChip U95Av2) contains 16 
probes; 5 probes forming the newly defined probe set b0805_9681 match all three transcript variants (b, c, and i) of SOD2; and 
8 probes (b0805_616) match the variants b and c; and the remaining 3 probes (b0805_11137) were mapped to the variant b 
only. The blue vertical line indicates the exon-intron boundaries or the beginning and ends of transcripts. The bottom panel of 
the figure shows the log-based 2 signals in the treatment and control groups for each probe. The values from all six samples 
were drawn here. The probes on x-axis were ordered from 5' to 3' of the gene.BMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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probes and targets the RefSeq entry NM_000636 which
encodes superoxide dismutase, mitochondrial (SOD2). A
"higher resolution" detailed view based on our probe-to-
transcript mapping shows that this probe set actually
maps to 3 AceView transcripts. Using our new probe set
definition, the first five probes form one probe set since
they all match transcripts SOD2.bAug05, SOD2.cAug05
and SOD2.iAug05; the next 8 probes match the transcript
set SOD2.bAug05 and SOD2.cAug05, so they form
another probe set, and the last 3 only match transcript
SOD2.bAug05 to form yet another group. Note that, in
our new probe set definition, probe sets never share
probes, but the transcripts they represent may overlap.
Some statistics of the newly defined probe sets for Affyme-
trix GeneChips U95A, U133A and U133 plus 2.0 are
shown in Table 1. In the majority of cases, our redefini-
tion splits an Affymetrix probe set into smaller probe sets;
for example, only about 17%, 15% and 22% of newly
defined probe sets maintain the original Affymetrix defi-
nition for the GeneChip U95A, U133A and U133 plus 2,
respectively. Unlike the nominally uniform size of all
original Affymetrix probe sets, such regrouping of probes
results in probe sets of varying sizes. For instance, the new
probe set size for the U95A chip ranges from 1 to 94
(median size, 5) and for the U133A chip, it ranges from 1
to 58 (median size, 4). The distribution of probe set sizes
for U95A and U133A chips are shown in Figure 2.
Because of the large transcript-to-gene ratio in AceView, a
majority of the probe sets match more than one AceView
transcript. Interestingly there is an inverse relationship
between probe set size and the number of transcripts a
probe set targets. The inverse relationship is especially
strong in probe sets derived by splitting, i.e. those probe
sets smaller than the standard Affymetrix probe sets (16
probes for U95A, 11 for U133A), but it is also apparent in
merged probe sets, i.e. those larger than the standard
Affymetrix probe sets.
Evaluation of the effect of probe set size on the detection 
of differential expression
We observed that increasing probe set homogeneity
resulted in smaller probe sets. For example, the redefini-
tion of probe sets on GeneChip U95A results in 20% of
the probe sets containing only 1 probe and 40% having
fewer than 4 probes (see Figure 3 for the probe set size dis-
tribution). To address how the probe set size influences
the identification of differential expression, we created 10
artificial data sets from the U133A Latin Square data. Each
data set contains expression measurements that are sum-
marized from randomly selected subsets (1–10) of probes
from each Affymetrix probe set. We chose the U133A
Latin Square data because all probes of the spike-ins are
known to accurately match their intended targets. By elim-
inating the influence of sequence specificity on gene
expression measurements, the results can be evaluated
solely on the basis of probe set size. All comparisons were
conducted using the evaluative tools in Affycomp [11,26],
and the RMA summarization algorithm was used to derive
summarized gene expression values.
To compare the overall variation in the data, we plotted
the inter-quartile range (IQR, a measure of variance) of
the log fold-changes for non-spiked-in probe sets (Figure
4A), and the average number of false positives (AFP;
counted when a fold-change is > 2 for non-spiked-in
probe sets; see Figure 4B) against the number of probes
used for deriving the expression measurements for the
probe sets. In both cases, an increased probe set size
improves the reliability of expression measurements as
shown by the lower variability and a significant reduction
in the number of false positives (Figure 4B). Notably,
there is a significant drop of both IQR and AFP when the
probe set size is greater than 3. Next, to evaluate the sensi-
tivity and specificity in detecting differential expression,
Receiver Operating Characteristic (ROC) curves were plot-
ted and compared (Figure 5). The average ROC curves for
expression measurements derived from 3, 4, 5 and 11
Table 1: Statistics of probe-to-transcript mapping and redefinition of probe sets
U95A U133A U133 Plus 2
Total probe sets from Affymetrix 12,413 22,238 54,630
Total probe sets, newly defined 22,609 38,416 70,092
Identical to original Affymetrix probe sets 3,804 (17%) 5,845 (15%) 15,376 (22%)
Derived from 1 Affymetrix probe set 16,916 (75%) 27,562 (72%) 45,217 (65%)
Derived from >1 Affymetrix probe sets 1,889 (8%) 5,009 (13%) 9,499 (14%)
Probe sets containing ≥ 4 probes 13,496 19,854 42,157
Total unique probe sequences (_at probes) 199,270 241,200 593,834
Probes matching ≥ 1 transcript in AceView 180,594 (91%) 216,395 (90%) 476,624 (80%)
Probes matching ≥ 1 transcript in RefSeq 162,888 (82%) 194,728 (81%) 312,021 (52%)
Total number of AceView transcripts matched 65,952 82,457 119,204
Total number of RefSeq transcripts matched 17,370 22,787 30,788
Probes matching non-human sequences or duplicated probe sequences were excluded from the calculation.BMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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The frequency distribution of the redefined probe set sizes for GeneChips U95A and U133A Figure 2
The frequency distribution of the redefined probe set sizes for GeneChips U95A and U133A. The number of 
probes in a redefined probe set is shown on the x-axis, and the frequency of probe sets is indicated on the left y-axis. The aver-
age number of transcripts (+/- SE, right y-axis) mapped by each probe set was also plotted against the probe set size. The upper 
and lower panels show U95A and U133A, respectively.
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probes (i.e. the original data) were drawn using all data
where the fold-change ranges from 2 to 4096 (Figure 5A)
and a subset of data where fold-change equals 2 (Figure
5B). Consistent with our earlier observations of reduced
variance, at a given false positive rate, we observed
increased power with increased probe set size. Impor-
tantly, the sensitivity-specificity ratio improved dramati-
cally when the probe set size was 4 or more.
Application of new probe set definition to biological 
datasets
By regrouping probes into homogeneous probe sets using
the AceView mapping, gene expression is examined at the
transcript level rather than the gene level. Higher resolu-
tion probe set definitions allowed us to identify specific
transcript variants that were initially undetectable within
the original heterogeneous probe sets. In an earlier exper-
iment using the Affymetrix platform, we compared pan-
creatic tumor cells prior to and after serum removal to
study early events accompanying islet cell differentiation
[27]. Here, this data set was reanalyzed with both the orig-
inal and the new probe set definitions and the two lists of
differentially expressed genes were compared. In this anal-
ysis, we consider a gene or a probe set differentially
expressed if the false discovery rate (FDR) adjusted p-
value is less than 0.05 and the fold-change (up or down-
regulated) is greater than 1.7.
First, we observe that a vast majority of genes were identi-
fied by both probe set definitions. Of the 425 Affymetrix
probe sets shown to be differentially expressed, 367
(86%) represent the same genes as those identified using
the new probe set definition. Although the gene lists
derived from both probe set definitions largely overlap,
the new probe set provides additional detailed informa-
tion on which set of transcripts are likely differentially
expressed. One example is shown in Figure 6. The Affyme-
trix probe set "33631_at" is significantly differentially
expressed (FDR adjusted p-value = 0.02), and it targets the
gene TXNL4A which has at least 6 transcript variants (see
the top-panel). Our new definition divides this probe set
into two new probe sets, one of which (circled in blue in
Figure 6) specifically targets transcripts d and e and seems
to be highly significant (FDR adjusted p-value < 0.01).
The other probe set (circled in red) targets potentially
many different transcript variants at the 3' end of the gene
and does not show significant difference in expression lev-
els between control and treatment samples (FDR adjusted
p-value = 0.23). In this example, applying the new probe
set definition clearly helps to identify the specific tran-
script variants that are likely differentially expressed. It
should be noted that such transcript-level information is
critical for designing probes and primers for Real-Time
PCR (RT-PCR) validation. For example, selecting the
primers/probes targeting the 3' end of TXNL4A as shown
in Figure 6 would mask the detection of expression level
differences between the treatment and control group.
The distribution of numbers of matching transcripts by the newly defined probe sets (U95A and U133A chip) Figure 3
The distribution of numbers of matching transcripts by the newly defined probe sets (U95A and U133A chip). 
The number of matching transcripts (shown on the horizontal axis) was plotted against the frequency of newly defined probe 
sets (y-axis). About 90% of the new probe sets match 10 transcripts or less.
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Table 2 lists genes which were identified as differentially
expressed by both the Affymetrix and the new probe set
definitions, but the new sets increased the resolution of
the assay, narrowing the detection of differential expres-
sion changes to a specific set of transcripts,
Comparing the two gene lists also identifies about 13–
16% of genes/probe sets which can only be identified as
being differentially expressed with either the original or
the new probe set definition. The majority of the genes
missed by either definition have p-values and fold-
changes close to the threshold chosen above (data not
shown), suggesting that the results using the two probe set
definitions are largely similar. However, in a few cases, we
observed that with higher resolution of the new probe set
definition, new transcript level changes are also uncov-
ered. One example is shown in Figure 1, where the probe-
level signals were plotted (bottom panel). The original
Affymetrix probe set "34666_at" is not considered to be
differentially expressed at the 5% significance level (FDR
adjusted p-value = 0.44). However, in our new AceView-
based definition, 16 probes in this probe set (shown in
Figure 1) were divided into 3 new probe sets. One probe
set (b0805_9681) which maps to transcript variants b, c,
and i of SOD2, appears to be significantly downregulated
(FDR adjusted p-value = 0.04, fold-change = 1.9); the
other two new probe sets map to variants b and c
(b0805_616) or to b (b0805_11137) only, and both
probe sets are not significantly changed (data not shown).
From these results, we can infer that variant i might be sig-
nificantly differentially expressed since it is being
uniquely interrogated by b0805_9681. Another example
is the Affymetrix probe set "37513_at" representing
Stearoyl-CoA desaturase (SCD). This gene was found to be
differentially expressed only by using the new definition
(FDR adjusted p-value = 0.02, fold-change = 2.3), and this
change was validated by real-time PCR (2.5-fold, p <
0.05).
Comparing cross-platform data using the new probe set 
definition
To further evaluate our probe set redefinition, we con-
ducted a full-scale transcript-level cross-platform compar-
ison. Most previous cross-platform analyses have utilized
gene-level annotations. We hypothesized that transcript-
level annotation of probe sets can be used to better match
probe identifiers across different microarray platforms,
thereby improving the consistency of cross-platform
measurements. Hence, two identifiers (one on each plat-
form) are matched if both map to a common set of
The effects of probe set size on variability and false positive detection using summarized gene expression measurements Figure 4
The effects of probe set size on variability and false positive detection using summarized gene expression 
measurements. These two figures are generated from data in the summarization table. The numbers of probes used for 
deriving the summarized expression measurements are plotted on the x-axis against (A) the IQR, used to indicate the level of 
variation of fold-changes (FC) of non-significant genes, and (B) the average number of false positives (called if FC>2 for non-
spike-in probe sets). All data were calculated using all arrays in the U133A Latin Square spike-in data set.
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AceView transcripts, whereas the original Affymetrix
probe sets were matched to Codelink probes using com-
mon UniGene identifiers (see Methods for details). Table
3 shows the cross-platform concordance measured by the
Pearson's correlation of log-ratios. The overall correlation
coefficients calculated using the UniGene-based matches
are about the same as those using the transcript-based
matches. However, after excluding the less reliable probe
sets (i.e. probe sets with fewer than 4 probes), the correla-
tion derived from transcript-based matches is higher
across three replicates (p = 0.03). The consistent, though
small, improvement in correlations suggests that there
may be better cross-platform comparability when the
transcriptome is probed with higherresolution. Similar
improvements are observed when using RefSeq-based
mapping by Dai et al [13]. Furthermore, we observed poor
correlation between the Affymetrix and CodeLink data for
newly defined Affymetrix probe sets with only 1, 2 or 3
probes, providing additional evidence that measurements
of newly defined probe sets with small probe set sizes (e.g.
less than 4 probes) are less reliable than those with larger
probe set sizes.
Discussion and conclusion
In this report we present a new approach to integrating an
up-to-date probe annotation into routine Affymetrix array
analysis. Although the Affymetrix GeneChip arrays are not
particularly designed to detect alternative transcripts, with
careful transcript-level annotation we have demonstrated
that specificity can be achieved by using the new probe set
definition. One of the advantages of using the newly rede-
fined probe sets is that it allows the examination of gene
expression in-depth at the transcript level, providing a
level of clarity in data interpretation unavailable at the
gene level or even at the RefSeq transcript level. With the
total number of AceView transcripts at 243,707 compared
with 39,115 in RefSeq, probes from all chips examined
matched approximately four times the number of tran-
scripts in AceView relative to ones annotated in RefSeq. In
addition, ~80% of all U133 Plus 2.0 array probes matched
AceView transcripts, which was ~50% more than the
number that matched to RefSeq. Such a detailed view is
necessary if one needs to design primers or probes for
quantitative-PCR verification. Moreover, our method nat-
urally separates the ambiguous and cross-hybridizing
probes and automatically groups gene specific probes.
The receiver operating characteristic (ROC) curves for expression measurements derived from various numbers of probes Figure 5
The receiver operating characteristic (ROC) curves for expression measurements derived from various num-
bers of probes. Comparison of gene expression measurements derived from 3, 4, 5, 6, and 11 probes is shown. The data 
summarized from 11 probes are the same as those derived from the original Affymetrix probe sets. The average ROC curves 
for (A) all the comparisons in the Spike-in dataset with fold changes ranging from 2 to 4092, and (B) for comparisons limited to 
data sets spiked-in at 2-fold.
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The interrogation of specific transcripts using the redefined probe sets Figure 6
The interrogation of specific transcripts using the redefined probe sets. The top panel shows the annotation of 
Affymetrix probes to AceVew transcripts, drawn by BLAT [44]. The Affymetrix probe set "33631_at" (on GeneChip U95Av2) 
contains 16 probes; 9 probes match two transcript variants (d and e) of TXNL4A, forming a new probe set by our definition 
(circled in blue); and the remaining 7 probes match the variants a, d, f and I, forming another new probe set (circled in red). 
The bottom panel of the figure shows the log-based 2 signals for each probe in the treatment and control groups (3 samples in 
each group). The probes on x-axis were ordered from 5' to 3' of the gene. Notice that the expression values are relatively 
homogeneous within each new probe set (separated by the vertical line, and the target transcripts were also circled in blue or 
red). The expression level differences between two groups are most clearly seen in the group on the left side (circled in blue).BMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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Although our approach to grouping probes into probe
sets is independent of the particular transcript database
being used, we consider AceView to be the most compre-
hensive and accurate database publicly available for con-
ducting such transcript-level reannotation of probes. In
comparison to RefSeq, which is a highly curated yet
incomplete mapping of the transcriptome, AceView anno-
tations identify on average, 5.0 transcripts per gene,
greatly exceeding that of RefSeq's 1.3 per gene. Further-
more, in annotating the ENCODE region[28], the quality
Table 2: Increased transcript specificity by using the newly defined probe sets
Affymetrix Probe Sets Redefined Probe Sets
Identifier Fold Gene symbol No. of variants Identifier Fold No. of variants Transcripts
38010_at 2.2 BNIP3 3 b0805_15050 2.24 2 BNIP3: a, b
31852_at 2.06 ANKMY2 3 b0805_979 2.01 2 ANKMY2: a, b
36813_at -3.15 TRIP13 3 b0805_19653 -3.94 2 TRIP13: a, e
38821_at 1.89 PGRMC2 3 b0805_3475 1.75 2 PGRMC2: a, d
33631_at -1.78 TXNL4A 5 b0805_2958 -2.71 2 TXNL4A: d, e
40916_at 1.97 BEXL1 3 b0805_642 2.35 2 BEXL1: a, c
39109_at -2.49 TPX2 4 b0805_8744 -2.44 2 TPX2: a, b
37985_at -1.78 LMNB1 3 b0805_7685 -1.75 2 LMNB1: a, c
34363_at 2.33 SEPP1 3 b0805_18077 6.87 2 SEPP1: c, f
37582_at 2.06 KRT15 4 b0805_20129 2.04 2 KRT15: a, c
34805_at -2.09 MGC2574 3 b0805_16254 -1.9 2 MGC2574: a, c
40117_at -2.26 MCM6 2 b0805_21229 -2.38 1 MCM6: a
37005_at 2.35 NBL1 3 b0805_14295 2.34 2 NBL1: a, b
40710_at 1.78 CLGN 2 b0805_21744 1.9 1 CLGN: b
36591_at -1.71 TUBA1 7 b0805_9382 -1.98 1 TUBA1: a
41583_at -2.98 FEN1 3 b0805_6644 -2.79 2 FEN1: a, c
35367_at 1.73 LGALS3 8 b0805_18811 1.78 2 LGALS3: a, c
41274_at 1.7 DKFZp667G21
10
2 b0805_4597 1.74 1 DKFZp667G21
10: a
39329_at -1.95 ACTN1 4 b0805_9591 -2.03 2 ACTN1: a, c
39809_at 2.19 HBP1 3 b0805_22136 2.17 2 HBP1: a, b
33891_at 2.77 CLIC4 2 b0805_15863 2.76 1 CLIC4: b
39441_at 2.92 LANCL1 2 b0805_1092 3 1 LANCL1: a
1884_s_at -2.12 PCNA 5 b0805_5909 -2.04 2 PCNA: a, b
41747_s_at 2.67 MEF2A 2 b0805_21100 3.22 1 MEF2A: e
35767_at 1.82 GABARAPL2 3 b0805_5736 2.01 2 GABARAPL2: a, 
c
41415_at -1.85 BYSL 3 b0805_3838 -2.07 2 BYSL: a, b
40414_at -2.44 VARS 4 b0805_873 -2.34 2 VARS: a, g
38728_at -2.06 NUP205 4 b0805_14227 -2.36 1 NUP205: a
39385_at -2.6 ANPEP 3 b0805_3943 -2.59 1 ANPEP: a
The probe set identifiers ending with "_at" are from Affymetrix; and those beginning with "b0805_" are newly defined here. Fold changes are ratios 
of the mean values of the treatment versus values of the control group, and the negative values indicate changes in the opposite direction.
Table 3: Pearson's correlations between Affymetrix and Codelink data
Cross-platform 
Comparison
Pearson's correlations
N D1/C1 D2/C2 D3/C3
UniGene-based match 7,399 0.55 0.55 0.58
AceView-based match 4,064 0.55 0.57 0.61
Probe sets with size ≥ 4 3,694 0.59 0.61 0.63
Probe sets with size < 4 370 0.34 0.37 0.39
RefSeq-based match* 7,801 0.60 0.61 0.64
The D1-D3 and C1-C3 are replicates in the treatment group and the control group respectively. The correlation is calculated on log-ratios, where 
the pairing of technical replicates is arbitrary. The best concordance between two platforms was observed using AceView-based transcript-level 
probe sets (with size ≥ 4) and RefSeq based probe sets.
*Using RefSeq-based mappings by Dai et al [13]BMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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of AceView transcript annotation has been shown to be
comparable with the gold-standard manual Havana
annotation. If the overall depth and quality was consid-
ered, among the 16 annotation approaches compared,
AceView is "by far the closest match" to the painstaking
manual transcript annotation [24].
As a result of maintaining homogenous probe sets and
excluding ambiguous and cross-hybridizing probes, this
new redefinition often results in small probe sets (i.e. hav-
ing fewer than 4 probes). Using a random sampling of
probes from the original Affymetrix probe sets, we dem-
onstrate that, without considering the annotation issue, at
least 4 probes may be required for deriving reliable expres-
sion measurements. From all the arrays studied, these ade-
quately sized probe sets comprise 58% of all new probe
sets. Our observation that probe sets with fewer than 4
probes yield poor data may arise from a number of fac-
tors. Non-functioning probes may exist for certain probe
sets: for instance, on the U95A chip, a number of probe
pairs for probe sets 407_at and 36889_at were found to
perform poorly [29]. Deviation of probe length on the
array from the designed 25-mer, due to synthesis ineffi-
ciency, may also contribute to both variability and poor
probe performance, including array-to-array variation
[30]. Non-functioning probes due to the latter case are
particularly difficult to trace and this problem is probably
only circumvented by integrating data from multiple
probes.
A recent paper by Dai et al [13] provided a method for
redefining Affymetrix probe sets using several gene and
transcript databases. Their regrouping strategy, however,
is fundamentally different from the current method in
that with their method, all probes that match a single tran-
script or gene are simply grouped into a probe set. How-
ever, their method does not generate "transcript-specific"
probe sets for genes with multiple transcripts, and does
not eliminate probe sets with multiple targets [17]. Hence,
there may be some probes within a newly regrouped
probe set that may actually cross-hybridize to a different
transcript. An example of this can be considered using Fig-
ure 1 to demonstrate. According to their method, tran-
script b (NM_000636) would utilize all probes from the
original Affymetrix probe set. With our redefinition, only
the last 3 probes (b0805_11137) are specific for this tran-
script. Furthermore, with their method, transcript c of
SOD2 will be represented by merging our newly redefined
probe sets, b0805_9681 and b0805_616. It is clear that
the probes from these different probe sets show gene
expression profiles that are markedly different. Thus, we
expect that the specificity and homogeneity within our
probe sets will result in more accurate gene expression
measurements, as recently suggested in [17]. To demon-
strate, using the RefSeq-based remapping of Dai et al,
there were clear differences in relative gene expression
changes obtained, examples of which are presented in
Supplemental Figures 1 (SOD2) and 2 (TXNL4A) [See
Additional file 1]. However, while these examples demon-
strate differences in individual results, they did not trans-
late into global improvements in the cross-platform
correlation using our current method over RefSeq-
mapped probe sets. A possible probe selection bias
towards abundant transcripts through the use of RefSeq-
based probe sets may account for this lack of difference.
The quality of the new probe set definition depends on a
number of factors. It is notable that 2–4% of probes on
the human arrays studied are ambiguous (i.e. they align to
multiple genes), and the resulting probe sets should be
used with caution. The gene(s) targeted by each new
probe set are made available in the annotation files down-
loadable from [35]. In addition, because of the relative
lack of information on poly-A sites, it should be stressed
that the current probe sets may not accurately reflect the
regulation that occurs at the level of alternative poly-ade-
nylation. For instance, regrouping of probes derived from
more than one Affymetrix probe set may have resulted
from poly-A sites currently unannotated in AceView. Con-
versely, there may have been some probe sets which are
split by the presence of partial cDNAs in AceView that do
not clearly define a poly-A site. As greater sequence cover-
age and refinement of the human genome become availa-
ble, a strategy such as described here would permit
continuous updating and refinement of probe sets, and
better interpretation of results, based on the latest knowl-
edge [15]. While we used AceView for redefining probe
sets, the method of regrouping probes can be applied
using any public or "in-house" database, and the guide-
lines provided here for creating a viable "probe set"
should be generally applicable. This method is also partic-
ularly relevant with the recently developed exon arrays
which have genome-wide probe content specific to indi-
vidual exons, observed or predicted. A method to estimate
quantitative expression data at the gene-level is suggested
in [31]. This approach employs a variety of annotations
for grouping probes into sets, followed by summarization
with the PLIER algorithm [32] or a derivative of it. How-
ever, we note that while transcript level annotations can
be derived from naturally homogeneous exon-level probe
sets, preliminary examination indicates that not all probe
sets are actually homogeneous. Exon array probes are
based on probe selection regions, or PSR, which are built
around "exon clusters" or overlapping exons that may or
may not share similar splice sites [33]. Hence exon arrays,
while providing a significant improvement over 3' expres-
sion arrays towards transcript specificity, may continue to
heterogeneously target multiple transcript variants. Since
an array design of 4 probes per single exon minimally sat-
isfies the requirements for a summarized expressionBMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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value, splitting these into smaller sets might further
degrade the accuracy of these probe sets. With the rising
number of alternative variants annotated in AceView and
elsewhere, transcript-specific arrays would require much
higher densities to achieve even greater resolution while
maintaining an adequate number of probes from which
to extract accurate expression data. As such, probes on
whole genome tiling arrays designed for transcript map-
ping could be grouped de novo based on AceView tran-
scripts and are a viable platform for this strategy.
In conclusion, our transcript-level reannotation and
redefinition of probe sets complement the original
Affymetrix design. Redefinitions introduce probe sets
whose sizes may not support reliable statistical summari-
zation; therefore, we advocate using our transcript-level
mapping redefinition in a secondary analysis step rather
than as a replacement. Knowing which specific transcripts
are differentially expressed is important to properly design
probe/primer pairs for validation purposes. The custom
chip-description-files (CDFs) and annotation files for our
new probe set definitions [35] are compatible with Bio-
conductor, with Affymetrix's Expression Console or third
party software.
Methods
Probe-to-transcript mapping and the redefinition of probe 
sets
We regrouped probes into probe sets based on AceView, a
comprehensive human transcript annotation database
[25]. The AceView transcripts are reconstructed from
mRNAs in three databases: GenBank, dbEST and RefSeq;
therefore, AceView shows a broader coverage and identi-
fies many more transcript variants than RefSeq alone [24].
Affymetrix probe sequences for the various types of Gene-
Chips were downloaded from [34]. Each probe sequence
was then matched against transcripts in AceView (Release
August 2005; human 35.4/hg17; non-cloud genes). Here
we named a probe by its Affymetrix probe set identifier
and the interrogation position (seen in downloaded
probe sequence files) separated by '-'. A probe is consid-
ered to match a transcript if the probe shares 22 or more
contiguous base pairs (bps) with that transcript sequence.
The length cutoff of 22 was chosen based on our empirical
observation that in the Affymetrix U95A spike-in dataset
(available at [29]), probes matching 22 bases of a tran-
script are capable of detecting 2-fold differences (data not
shown). Through this mapping procedure, we constructed
a hash table where the keys and values are probe
sequences and sets of AceView transcript identifiers,
respectively. Next, probes are grouped into a probe set if
they all match exactly the same set of transcripts (as
shown in Figure 1). If a probe does not share transcript
mapping with any other probe, it is assigned as an inde-
pendent probe set. The naming of newly defined probe
sets is somewhat arbitrary. A set of tab-delimited files con-
taining the annotation of newly defined probe sets,
including probe set names, the original Affymetrix probe
set definition, gene symbol(s) and description, are availa-
ble for download at [35]. The chip description files
(CDFs) required for mapping the probe positions on the
chips to the sequence annotation were made using the R
package "altcdfenvs" [22,36], These CDF files and corre-
sponding CDF packages are compatible with other bio-
conductor packages, such as "affy", to derive expression
summary values for the newly defined probe sets, and are
available for download as well [35]. In addition, custom
CDF files which are compatible with third party software
are also available for download.
Performance testing using size-based definition of 
Affymetrix probe sets
To evaluate how many probes in a probe set are required
to derive a robust expression measurement, we ran a sim-
ulation to test the accuracy and consistency of a standard
data set where probe sets are redefined based on having
different sizes (i.e. having different numbers of probes).
To do this, all probe sets for the U133A Genechip were
artificially redefined by size (denoted as d1, d2, ..., d10),
by randomly sampling various numbers of probes from
the original probe sets. For example, the original Affyme-
trix probe set on GeneChip U133A has 11 probes; how-
ever, in our artificial probe set definition, say d2, each
probe set only contains 2 probes which are randomly
drawn from the corresponding original Affymetrix probe
sets. Next, using the R package altcdfenvs, we built 10 chip
design files (CDF), with each corresponding to a probe set
size-based definition.
Using these CDF files and standard summarization
approach RMA [6], we generated 10 artificial data sets
from the original U133A Spike-In data sets downloaded
from the Affymetrix website [29]. The "affy" package in
bioconductor was used to read and process the raw.cel
files. To make comparisons consistent, the array preproc-
essing is the same for all simulated datasets, using the
CDF file from Affymetrix (the default in affy). We chose
RMA background correction and quantile normalization
[6]. The normalized probe-level expression data was then
used for deriving gene expression summary values. Since
a set of standard evaluation tools are available in Biocon-
ductor's "affycomp" package [9,11] for generating a series
of comparison plots and summarization tables, we used it
to compare the gene expression summaries derived from
different-sized probe sets. The 10 sets of expression meas-
urements from the simulation study are available for
download at our website [35].BMC Bioinformatics 2007, 8:108 http://www.biomedcentral.com/1471-2105/8/108
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A cross-platform comparison and analysis of a biological 
data set
The expression data for Affymetrix and Codelink were
obtained as described in [27]. In the cross-platform com-
parison, we compared RNAs from 6 samples: 3 technical
replicates from PANC-1 cells grown in serum-rich
medium (the control group) and 3 replicates from cells
one day after the serum was removed (the treatment
group). Identical RNA samples were applied to the
Affymetrix U95Av.2 arrays and the Codelink UniSet
Human I Bioarrays from Amersham (30 mer oligonucle-
otide probes). The raw expression data from both plat-
forms are available at [37]. For the Affymetrix platform,
data were pre-processed and normalized using the RMA
method available in the bioconductor "affy" package [38].
For the Codelink data we used quantile normalization as
used in RMA, and only probes with measurements labeled
as "Good" across all 6 samples were included in our anal-
ysis. Next, the three individual log2 ratios of expression
values for the treatment versus control samples were cal-
culated, where the pairing of a sample in the control
group with a sample in the treatment group is arbitrary.
These log-ratios were used as recommended [39] to calcu-
late and compare the Pearson's correlations for data from
the two platforms. The probe identifiers from the two
platforms were cross-mapped by two methods: the Uni-
Gene IDs [40] and the AceView transcripts. First,
RESOURCERER [41] (version July 2005) was used to carry
out the UniGene-based mapping between the Codelink
identifiers and the original Affymetrix probe sets. The
AceView-based mapping is straightforward: a Codelink
probe is considered matching a newly defined Affymetrix
probe set if both are mapped to the same set of AceView
transcripts.
We conducted a comparison between two groups (cells
with serum versus cells with one-day after serum removal)
using our newly defined probe sets and the original
Affymetrix probe sets. For simplicity we averaged data
from 3 technical replicates into one biological replicate in
each group (so each group contains three biological repli-
cates). For the new probe set definition, probe sets with 3
or less probes were excluded from the analysis. The empir-
ical Bayes method [42] was applied to calculate t-statistics
and p-values and the p-values were further adjusted by the
False Discovery Rate (FDR) approach using the "p.adjust"
function in the "limma" package [43].
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